Skip to main content
. 2021 Jul 8;30(11):1705–1721. doi: 10.1177/09612033211028653

Figure 1.

Figure 1.

Key milestones in the development of belimumab and the treatment of SLE and LN.

BLyS: B-lymphocyte stimulator; EMA: European Medicines Agency; FDA: Food and Drug Administration; GSK: GlaxoSmithKline; HGS: Human Genome Sciences; LN: lupus nephritis; SLE: systemic lupus erythematosus; ST: standard therapy for SLE; TIGR: The Institute for Genomics Research.